All In Biotech

Drug Trial Radar · NCT02069899

A Study for Long-term Follow-up of Hemophagocytic Lymphohistiocytosis (HLH) Participants Who Received Treatment With Emapalumab (NI-0501), an Anti-interferon Gamma Monoclonal Antibody

A Multicenter Study for the Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody

Last checked: Nov 20, 2026Latest source record: Jun 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

58

Actual

Start

Aug 4, 2014

Primary completion

May 18, 2021

Study completion May 18, 2021

Sponsor

Lead sponsor
Swedish Orphan BiovitrumIndustry
Sponsor type
Industry
Collaborators
Seventh Framework Programme
First posted
Feb 24, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

International, multicenter, long-term, follow-up study that will enrol HLH participants who have received emapalumab in previous clinical trials, in the context of the clinical development program for emapalumab or under compassionate use (CU).

Conditions

  • Hemophagocytic Lymphohistiocytosis

Interventions

  • EmapalumabDrug

    Treatment with emapalumab is not planned for all enrolled participants. For participants who will continue receiving emapalumab in the context of this study (NI-0501-05), the dose and timing will be either carried forward from the last administered emapalumab dose as part of the parent study in which the participant was enrolled, or an adjusted dose will be administered, if necessary.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Event (AE)Time frame: From the date of enrollment in this study up to 1 year either after HSCT or after the last administration of emapalumab (maximum duration: 639 days)

Locations

16 sites in 5 countries. Site status is shown where the registry gives one.

  • Spectrum Health Helen Devos Children's Hospital

    Grand Rapids, Michigan

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • Cincinnati Children's Hospital - Division of Immunobiology

    Cincinnati, Ohio

  • Cincinnati Children's Hospital

    Cincinnati, Ohio

  • Texas Children's Cancer Center

    Houston, Texas

  • Hôpital Necker-Enfants Malades

    Paris, France

  • Fondazione MBBM c/o Ospedale San Gerardo Clinica Pediatrica

    Monza, Italy

  • Azienda Ospedaliera Padova

    Padova, Italy

  • Ospedale Pediatrico Bambino Gesu - UO Reumatologia

    Rome, Italy

  • Ospedale Pediatrico Bambino Gesu

    Rome, Italy

  • Ospedale della Donna e del Bambino - U.O.C. Oncoematologia Pediatrica

    Verona, Italy

  • Hospital Universitario Vall d'Hebron Servei de Hematologia i Oncologia

    Barcelona, Spain

  • Sant Joan de Déu Hospital - Pediatric Rheumatology Department

    Barcelona, Spain

  • Hospital Universitario Niño Jesús Servicio de Hemato-Oncología Pediátrica

    Madrid, Spain

  • UCL Institute of Child Health Great Ormond Street Hospital

    London, United Kingdom

  • Great Ormond Street Hospital - Department of Haematology

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.